Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Influx Healthtech IPO
Influx Healthtech Ltd
₹1,09,200 /1200 sharesMinimum Investment
Influx Healthtech IPO Listing Details
| Listed On | Issue Price | Listing Price | Listing Gains |
|---|---|---|---|
| -- | ₹96.00 | ₹132.50 | ₹36.50 (38.02%) |
Influx Healthtech IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 18 Jun ‘25 - 20 Jun ‘25 | ₹1,09,200 | 1,200 | ₹91 - ₹96 |
| Issue Size | IPO Doc |
|---|---|
| 58.57Cr | RHP PDF |
Subscription rate
As of 20 Jun'25, 05:00 PM
| Qualified Institutional Buyers | 13.12x |
| Non-Institutional Investor | 115.70x |
| Retail Individual Investor | 69.04x |
| Total | 58.65x |
About Influx Healthtech
Founded in
2020
Managing director
Mr Munir Abdul Ganee Chandniwala
Parent organisation
Influx Healthtech Ltd
Strengths & Financials of Influx Healthtech
Strengths
Risks
Influx Healthtech claims to have a broad and diverse product portfolio, including multi-nutritional tablets, dietary supplements, Ayurvedic products, oral dispersible films, gummy candies, and more.
The company claims to serve a wide range of industries, including cosmetics, pharmaceuticals, and home care.
The company holds ISO 22000:2018 certification for food safety management systems, ISO 14001:2015 certification for environmental management systems, and approval from the Food and Drug Administration (FDA) for its products.
Influx Healthtech claims to have a specialised formulation development department that focuses on creating innovative, market-ready solutions for nutraceuticals, cosmetics, Ayurvedic products, and veterinary formulations.
The company has witnessed a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 76.06 crore in FY23 to Rs 99.96 crore in FY24 and Rs 104.85 crore in FY25. PAT increased from Rs 7.20 crore in FY23 to Rs 11.13 crore in FY24 and Rs 13.37 crore in FY25.
The company’s manufacturing facilities are concentrated at one location – Palghar, Thane, Maharashtra. Any adverse political, social, or economic development in this region could be detrimental to the company’s operations and business prospects.
The top 10 customers accounted for 47.89 percent, 50.10 percent, and 46.29 percent of the company’s revenue in FY25, FY24, and FY23. Any failure to retain these key customers, expand the customer base, or a loss of business from these clients can adversely affect the company’s business and financial standing.
The top 10 suppliers accounted for Rs 25.90 crore (36.38 percent) of the company’s supplies in FY25, Rs 26.98 crore (39.44 percent) in FY24, and Rs 20.55 crore (38.84 percent) in FY23. Any disruption in supplies from one or more of these suppliers could adversely affect the company’s business and finances.
A significant portion of the company’s revenue is derived from Maharashtra. It accounted for Rs 65.77 crore (62.71 percent) of the company’s sales in FY25, Rs 66.88 crore (66.90 percent) in FY24, and Rs 45.82 crore (60.25 percent) in FY23. Any disruption in this region could negatively impact the company’s business.
A significant portion of the company’s sales is derived from the nutraceutical segment. It accounted for Rs 94.04 crore (89.69 percent) of the company’s revenue in FY25, Rs 93.47 crore (93.50 percent) in FY24, and Rs 71.61 crore (94.14 percent) in FY23. Any downturn in this sector or an inability to manage and grow sales effectively could have a detrimental impact on the company’s business and operations.
Influx Healthtech is vulnerable to raw material price fluctuations due to its heavy reliance on third-party suppliers and spot market sourcing. The lack of long-term agreements and challenges in passing on cost increases to customers may impact the company’s margins and profitability, potentially leading to production delays and customer losses.
The company, its promoters, directors, promoter group, and group companies are involved in certain ongoing legal proceedings. Any adverse judgments in any of these cases could be detrimental to the company’s business prospects.
Influx Healthtech Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Influx Healthtech IPO
| Apply as | Price band | Apply upto |
|---|---|---|
| Regular | ₹91 - 96 | ₹2 - 5 Lakh |
| High Networth Individual | ₹91 - 96 | ₹2 - 5 Lakh |
For Influx Healthtech IPO, eligible investors can apply as Regular.